Pembrolizumab plus BEAM with stem cell transplant for Hodgkin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to the standard BEAM chemotherapy before a stem cell transplant can help people with relapsed Hodgkin lymphoma. It's for patients who are eligible for a transplant and have stable organ function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You need to be healthy enough for a stem cell transplant using your own cells.
- You should be able to take care of yourself (performance status score of 0 or 1).
- Your liver, kidneys, and blood counts must work well enough (tested within 14 days of joining).
- If you have hepatitis B, C, or HIV, you must have it under control with medication.
- You cannot have had a serious autoimmune reaction to an immunotherapy drug before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the immunotherapy drug pembrolizumab with chemotherapy for people with newly diagnosed Hodgkin lymphoma who are too frail for standard treatment. The goal is to find a safer, effective option for patients who are older or have other health issues.
This Phase 2 trial tests whether pembrolizumab plus brentuximab works better than standard chemotherapy followed by an autologous stem cell transplant for people whose classic Hodgkin lymphoma has come back or did not respond. It may help by improving cancer control before and around stem cell transplant and by comparing outcomes between the two treatment approaches.
This trial is testing a new treatment for people with a type of lymphoma (DLBCL) that has not gone away or has come back. It combines a study drug called pirtobrutinib with a common chemotherapy regimen (BEAM) before a stem cell transplant, and the goal is to see if this approach is safe and effective in helping patients get to transplant.
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
This study tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy bendamustine can help people with Hodgkin lymphoma whose cancer returned or did not respond to earlier treatment. The goal is to see if this two-drug combination works better than either drug alone.
This Phase 3 study compares two chemotherapy schedules (Chi-BEAM vs BEAM) given before an autologous stem cell transplant to treat newly diagnosed peripheral T-cell lymphoma that responded to first-line treatment. If you fit the lab and heart/lung requirements, it may offer access to a new treatment approach designed to improve outcomes.
Hear when a new Classic Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.